cell line that contains SV40 T antigen and allows episomal replication of SV40 origin containing plasmids. We transfected a pCDM8/HeLa cDNA expression library into these cells, thereby causing overexpression of the plasmid-encoded genes. The transfected cells were treated with immunotoxin to select for resistance-mediating plasmids, which were reisolated from these cells and amplified in Escherichia coli.
INTRODUCTION
oping mutations that interfere with toxin internalization, intracellular transport and processing (10) (11) , or by alteration of elongation factor 2, the intracellular target of PE (12) (13) (14) (15) (16) . Resistance to conventional chemotherapeutic agents has been widely studied, and many mechanisms have been elucidated. In some cases, resistance is due to structural gene mutations. In others, it is due to enhanced expression of a normal cellular gene. For example, overexpression of the human MDR1 gene or of the DHFR gene leads to drug resistance (17) (18) (19) (20) (21) .
Here we describe the isolation of plasmids that render cells resistant to an immunotoxin composed of MAb B3 and PE. To do this, a human cDNA expression library with an SV40 origin was introduced into T antigen containing MCF-7 breast cancer cells which were then treated with the immunotoxin B3(Fv)-PE38KDEL to select for resistance-mediating cDNA plasmids. Plasmids mediating resistance are enriched by two additional cycles of transfection and selection and then used to make immunotoxin-resistant, stable MCF-7 cell lines. These plasmids also confer resistance to PE itself and to diphtheria toxin (DT), but not to ricin or cycloheximide. The approach described should also be useful in identifying cDNAs responsible for other types of toxin as well as for drug resistance.
MATERIALS AND METHODS

Materials
Monoclonal antibody B 3, B 3 -immunotoxins, and PE were produced and purified in our lab (4, 7, 22) . DT, ricin, and cycloheximide are from Sigma. A HeLa cDNA library in pCDM8 was from Clontech, pMClneo/polyA from Stratagene and pCMV-TAg a gift from V. Ogryzko (23 Methods for construction of MCF-7/T and the cDNA library and for details of the electroporation). HeLa cells are resistant to B 3 (Fv) -PE38KDEL, whereas MCF-7 cells and MCF-7/Tcells which permit episomal replication of plasmids with a SV40 origin of replication are sensitive to the immunotoxin. Two days after electroporation, cell pools were treated with 10 ng/ml of B3(Fv)-PE38KDEL, a concentration that has previously been found to kill >99% of MCF-7 cells (9). Three days later, microscopic inspection revealed that most of the cells were dead and had detached from the culture dish. The dishes were then washed, the remaining cells harvested by trypsinization, and the episomal plasmids recovered in Hirt supernatants. The reisolated plasmid pools were then transformed and amplified in E. coli and retransfected into MCF-7/T for two further rounds of immunotoxin selection and plasmid reisolation. This procedure of plasmid transfection, immunotoxin selection, and plasmid reisolation is summarized in Fig. 1 . Because treatment of MCF-7 cells with immunotoxin results in the detachment of dying and dead cells (i.e., cells that do not contain resistance-mediating plasmids), these were removed in the washing step prior to plasmid reisolation. Therefore, this procedure enriches for plasmids that cause cells to remain alive and attached to the plate after immunotoxin exposure. In the three cycles of transfection and selection, we observed a 100-fold increase of plasmid clones recovered. After selection, we obtained 1 (23) and pMClneo polyA (Stratagene) and subsequent G418 selection at 0.8 mg/ml as described in Materials and Methods. and MCF-7/T cells have the same morphology and sensitivity to PE and B3-derived immunotoxins but MCF-7/T appears to grow slightly slower. MCF-7/T were transfected with a pCDM8/HeLa cDNA expression library, treated with 10 ng/ml immunotoxin (B3(Fv)-PE38KDEL) (9) ; and three days later the flasks were washed with PBS, and the remaining cells were trypsinized, plasmids reisolated from them (25) and transformed into E. coli MC 1061 /P3. Aliquots of the transformations were used to determine the number of recovered plasmids (cfu) in E. coli, the remainder was grown for preparation of plasmid pools to be again transfected into MCF-7/T for more rounds of selection. After the third round of transfection-selection, stable MCF-7 transfectants were made by cotransfection of single isolated plasmids and pMClneo/polyA. which do not confer resistance but are rescued in MCF-7/T cells by the simultaneous presence of a resistance plasmid. Selectively amplified plasmids that confer resistance are likely to occur more frequently than contaminating random plasmids and thus should be easily detectable by hybridization analysis. We 
Ninety-six plasmid clones from the third round of selection were hybridized with inserts of 10 Fig. 2B , the transfectants also are resistant to PE. The IC50s were 1 ng/ml PE for the controls and between 5 ng/ml and 15 ng/ml for the plasmid containing cells. Decreased sensitivity of the transfectants was also demonstrated by colony formation assays in which cells were treated with various amounts of PE for two days, and then after trypsinization their ability to form colonies were assessed ( Table 2) . Compared with the control cell line, the numbers of colonies obtained in these assays was 4-to 11-fold higher at 3 ng/ml PE. This increase in resistance is in accord with the decreased toxin sensitivity observed in the MTS proliferation assays. At 10 ng/ml PE, the number of colonies of the MCF-7 transfectants was between 36-and 80-fold higher than the controls and at 30 ng/ml PE no colonies were observed with control cells, while the transfectants still yielded between 100 and 250 colonies each.
Finally, we analyzed whether resistance was Colonies were visualized 6 days after plating by methylene-blue staining, and the colony numbers (cfu) calculated by the colonies/well x dilution factor. *MCF-7/90 was treated with identical conditions but in a separate experiment.
limited to PE and PE containing immunotoxins or if the plasmids also mediated resistance to other toxins that inhibit protein synthesis. Figure  2 C-E shows experiments (MTS assays) in which the cells were treated with diphtheria toxin (DT), ricin, or cycloheximide. We found that the transfectants were also less sensitive to DT, a toxin that, like PE, inhibits protein synthesis by ADPribosylation of EF2 (2, 5, (12) (13) (14) . In contrast, the transfectants exhibited no resistance to ricin or cycloheximide, which both inhibit protein synthesis by interacting with ribosomes. (DT) . However, resistance to ricin or cycloheximide, which both inhibit protein synthesis but by different mechanisms, was not affected. We also did not observe significant differences in sensitivity towards various low molecular weight anticancer drugs (VP16, actinomycin D, vincristine, colchicine, taxol, daunorubicin, or mitomycin C, data not shown). This suggests that the mechanism(s) by which these resistances arise is related to the common site of action of PE and DT which both inhibit protein synthesis by ADP-ribosylation of EF2.
Although their amino acid sequences are dissimilar, PE and DT have many similarities in the manner in which they kill target cells. Both must be internalized by receptor-mediated endocytosis and undergo proteolytic processing and reduction in order to generate an active fragment that can translocate to the cytosol where EF2 is located (2,5,10-16). Furthermore, both can only ADP-ribosylate diphthamide modified EF2. Cellular mutations that mediate toxin resistances have been described which include resistances to PE caused by a processing defect (10) or alterations in vesicle acidification and transport or by mutations in EF2 which do not allow toxin mediated ADP-ribosylation (1 1-15 ). Furthermore, it is possible that mutations that affect other, so far uncharacterized cellular factors (possibly unfolding enzymes) (16) can cause toxin resistance. We have investigated and eliminated some of these possibilities. It is unlikely that proteolytic processing is affected by the resistance plasmids, because the cells are resistant to both proteolytically "'nicked" as well as '"unnicked" DT (data not shown). We can also exclude expression of a mutated, toxin-resistant EF2 gene, since preliminary analysis of the sequences of the isolated clones shows they do not contain sequences resembling the EF2 gene. In fact, all the sequences analyzed so far encode unknown cDNAs (data not shown). We think that another more likely explanation for resistance could be that the plasmids contain cDNAs or cDNA fragments derived from normal cellular genes, whose "deregulated" overexpression cause the resistance phenotype. It is well known, for example that overexpression of the multidrug-resistance gene (MDR1 ) in human cancers can cause resistance of cells towards various chemotherapeutic agents (17) . Alternatively, the plasmids might contain and express cDNA or short cDNA fragments in an inverse orientation; such antisense transcripts have been found to reduce expression of a corresponding cellular gene and produce resistance to VP16 (34) . We are presently analyzing some of the resistant MCF-7 transfectants and plasmids in detail to elucidate their resistance mechanisms.
The results presented here suggest that cancer cells can become toxin resistant by deregulated expression of normal cellular genes. It is possible that resistances based on these mechanisms could develop in vivo and limit the success of immunotoxin therapy. Clinical trials that have already been initiated and will be expanded in the next few years will show if the mechanism of toxin resistance identified by selection cloning will be an impediment to the immunotoxin therapy of cancer.
